INmune Bio Inc. (NASDAQ: INMB)
$9.23
-0.6300 ( -6.39% ) 52.7K
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.
Market Data
Open
$9.23
Previous close
$9.86
Volume
52.7K
Market cap
$182.59M
Day range
$9.15 - $9.89
52 week range
$6.50 - $14.74
SEC Fillings
| Form Type | Description | Pages | Date |
|---|---|---|---|
| 8-k | 8K-related | 19 | Apr 22, 2024 |
| 10-k/a | Quarterly Reports | 17 | Apr 16, 2024 |
| 8-k | 8K-related | 15 | Apr 09, 2024 |
| 8-k | 8K-related | 15 | Mar 29, 2024 |
| 10-k | Annual reports | 82 | Mar 28, 2024 |
| 8-k | 8K-related | 15 | Mar 27, 2024 |
| 8-k | 8K-related | 16 | Jan 30, 2024 |
| 8-k | 8K-related | 14 | Jan 02, 2024 |
| 8-k | 8K-related | 13 | Dec 18, 2023 |
| 8-k | 8K-related | 13 | Dec 18, 2023 |